AR107973A1 - 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj - Google Patents

6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj

Info

Publication number
AR107973A1
AR107973A1 ARP170100736A ARP170100736A AR107973A1 AR 107973 A1 AR107973 A1 AR 107973A1 AR P170100736 A ARP170100736 A AR P170100736A AR P170100736 A ARP170100736 A AR P170100736A AR 107973 A1 AR107973 A1 AR 107973A1
Authority
AR
Argentina
Prior art keywords
substituted
independently selected
case
cr7r7
alkyl
Prior art date
Application number
ARP170100736A
Other languages
English (en)
Inventor
Xiaojun Zhang
George O Tora
Monique Phillips
Michael C Myers
Wei Meng
R Michael Lawrence
James A Johnson
Wen Jiang
Heather Finlay
Robert Paul Brigance
Donna M Bilder
Zulan Pi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR107973A1 publication Critical patent/AR107973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o un estereoisómero, un enantiómero, un diastereoisómero, un tautómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde: alk es C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ; el anillo B se selecciona independientemente de C₃₋₆ cicloalquilo, C₃₋₆ cicloalquenilo, arilo, carbociclilo bicíclico y heteroarilo de 6 miembros; R¹, en cada caso, se selecciona independientemente de H, halógeno, NO₂, -(CH₂)ₙORᵇ, (CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, -(CH₂)ₙCN, -(CH₂)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-carbociclilo sustituido con 0 - 3 Rᵉ; R² se selecciona independientemente de C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ; C₂₋₅ alquenilo sustituido con 0 - 3 Rᵉ, arilo sustituido con 0 - 3 Rᵉ, heteroarilo sustituido con 0 - 3 Rᵉ y C₃₋₆ cicloalquilo sustituido con 0 - 3 Rᵉ; siempre que, cuando R² es C₁₋₅ alquilo, el átomo de carbono y los grupos unidos a este, salvo el que está unido al anillo de pirimidina, se puedan reemplazar por O, N y S; R³ se selecciona independientemente de H y C₁₋₅ alquilo; R⁴ se selecciona independientemente de -(CR⁷R⁷)ₙ-R⁶, -(CR⁷R⁷)ₙOR⁶, -(CR⁷R⁷)ₙS(O)ₚR⁶, -(CR⁷R⁷)ₙC(=O)R⁶, -(CR⁷R⁷)ₙNRᵃR⁶, -(CR⁷R⁷)ₙNRᵃC(=O)R⁶, -(CR⁷R⁷)ₙS(O)ₚNRᵃR⁶ y -(CR⁷R⁷)ₙNRᵃS(O)ₚR⁶; de manera alternativa, R³ y R⁴, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico o un anillo espiro heterocíclico que comprende átomos de carbono y 1 a 4 heteroátomos adicionales seleccionados de NR⁵ᵃ, O y S, y sustituidos con 0 - 5 R⁵; R⁵, en cada caso, se selecciona independientemente de OH, halógeno, -(CR⁷R⁷)ₙ-R⁶, -OR⁶, -S(O)ₚR⁶, -C(=O)R⁶, -NRᵃR⁶, -C(=O)NRᵃR⁶, -NRᵃC(=O)R⁶, -NRᵃC(=O)OR⁶, -OC(=O)NRᵃR⁶, -C(=O)OR⁶, -S(O)ₚNRᵃR⁶, -NRᵃS(O)ₚNRᵃR⁶ y -NRᵃS(O)ₚR⁶; R⁵ᵃ, en cada caso, se selecciona independientemente de -C(=O)OR⁶, C(=O)NRᵃR⁶, -(CR⁷R⁷)ₙ-R⁶, -C(=O)-R⁶ y -S(O)ₚR⁶; R⁶, en cada caso, se selecciona independientemente de -(CR⁷R⁷)ₙ-C₃₋₁₀ carbociclilo y -(CR⁷R⁷)ₙ-heteroarilo, cada uno sustituido con 0 - 3 R⁸; R⁷, en cada caso, se selecciona independientemente de H, C₁₋₄ alquilo y (CH₂)ₙ-C₃₋₁₂ carbociclilo sustituido con 0 - 3 Rᵉ; R⁸, en cada caso, se selecciona independientemente de H, halógeno, -(CH₂)ₙORᵇ, (CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, (CH₂)ₙCN, -(CH=)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ, (CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; Rᵃ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente de C₁₋₆, alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₄ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente de F, Cl, Br, CN, NO₂, =O, CO₂H, C₁₋₆ alquilo sustituido con 0 - 5 Rᶠ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ₙ-C₃₋₆ cicloalquilo, -(CH₂)ₙ-C₄₋₆, heterociclilo, -(CH₂)ₙ-arilo, -(CH₂)ₙ-heteroarilo, -(CH₂)ₙORᶠ, S(O)ₚRᶠ, C(=O)NRᶠRᶠ, NRᶠC(=O)Rᶠ, S(O)ₚNRᶠRᶠ, NRᶠS(O)ₚRᶠ, NRᶠC(=O)ORᶠ, OC(=O)NRᶠRᶠ y -(CH₂)ₙNRᶠRᶠ; Rᶠ, en cada caso, se selecciona independientemente de H, F, Cl, Br, CN, OH, C₁₋₅ alquilo (de manera óptima, sustituido con halógeno y OH), C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; n en cada caso, se selecciona independientemente de 0, 1, 2, 3 y 4; y p en cada caso, se selecciona independientemente de 0, 1 y 2.
ARP170100736A 2016-03-24 2017-03-23 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj AR107973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312780P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
AR107973A1 true AR107973A1 (es) 2018-07-04

Family

ID=58464691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100736A AR107973A1 (es) 2016-03-24 2017-03-23 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj

Country Status (22)

Country Link
US (2) US10106528B2 (es)
EP (1) EP3433247B1 (es)
JP (1) JP6716711B2 (es)
KR (1) KR102433280B1 (es)
CN (1) CN109195963B (es)
AR (1) AR107973A1 (es)
AU (1) AU2017238504B2 (es)
BR (1) BR112018068341A2 (es)
CA (1) CA3018346A1 (es)
CL (1) CL2018002671A1 (es)
CO (1) CO2018011105A2 (es)
EA (1) EA037162B1 (es)
ES (1) ES2895124T3 (es)
IL (1) IL261904B (es)
MA (1) MA43761A (es)
MX (1) MX2018011194A (es)
MY (1) MY189454A (es)
SG (1) SG11201808163WA (es)
TW (1) TWI744301B (es)
UY (1) UY37169A (es)
WO (1) WO2017165640A1 (es)
ZA (1) ZA201806356B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104884A1 (es) 2015-06-03 2017-08-23 Bristol Myers Squibb Co Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
KR20180067599A (ko) 2015-10-14 2018-06-20 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
KR20180095577A (ko) 2015-12-16 2018-08-27 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논
JP6716711B2 (ja) * 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
WO2018071622A1 (en) 2016-10-14 2018-04-19 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541804A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH602664A5 (en) * 1973-06-14 1978-07-31 Sandoz Ag 2-Tert. amino-alkylamino-pyrimidine derivs.
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US6943173B2 (en) 2000-07-18 2005-09-13 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
JP2006508030A (ja) 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
WO2003099211A2 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007510652A (ja) 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
CN1898215A (zh) 2003-12-19 2007-01-17 默克公司 有丝分裂驱动蛋白抑制剂
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007124397A2 (en) 2006-04-21 2007-11-01 Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
PL2079707T3 (pl) 2006-10-10 2015-05-29 Proionic Gmbh Sposób wymiany 1,3-hetero-aromatycznych 2-karboksylanów z wodą
CL2008000065A1 (es) * 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US20110253929A1 (en) 2008-12-22 2011-10-20 Basf Se Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors
WO2010132999A1 (en) 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN103140221A (zh) 2010-08-10 2013-06-05 盐野义制药株式会社 新型杂环衍生物和含有其的药物组合物
US9518068B2 (en) 2011-05-31 2016-12-13 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
EP2715858A1 (en) 2011-05-31 2014-04-09 Merck Patent GmbH Electrolyte formulations
WO2014004676A1 (en) 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
MD20150122A2 (ro) 2013-06-27 2016-05-31 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
EP2997106B1 (de) 2013-11-29 2019-03-06 proionic GmbH Verfahren zum aushärten eines klebstoffs mittels mikrowellenbestrahlung
WO2015184011A2 (en) 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonists of the apelin receptor and methods of use thereof
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
CN107709299B (zh) 2015-04-24 2021-07-16 盐野义制药株式会社 6元杂环衍生物及含有其的药物组合物
UA119932C2 (uk) 2015-05-20 2019-08-27 Емджен Інк. Триазолові агоністи рецептора apj
AR104884A1 (es) * 2015-06-03 2017-08-23 Bristol Myers Squibb Co Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
KR20180067599A (ko) 2015-10-14 2018-06-20 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
EP3380970B1 (en) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Novel azole derivatives as apelin receptor agonist
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
KR20180095577A (ko) 2015-12-16 2018-08-27 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논
JP6716711B2 (ja) * 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮

Also Published As

Publication number Publication date
SG11201808163WA (en) 2018-10-30
JP6716711B2 (ja) 2020-07-01
EA201892123A1 (ru) 2019-02-28
ZA201806356B (en) 2021-05-26
CL2018002671A1 (es) 2019-01-25
TW201736362A (zh) 2017-10-16
WO2017165640A1 (en) 2017-09-28
MA43761A (fr) 2021-05-05
EA037162B1 (ru) 2021-02-12
JP2019509319A (ja) 2019-04-04
US20190002441A1 (en) 2019-01-03
AU2017238504A1 (en) 2018-11-15
MY189454A (en) 2022-02-14
CN109195963B (zh) 2021-04-23
TWI744301B (zh) 2021-11-01
KR20180129836A (ko) 2018-12-05
US20170275272A1 (en) 2017-09-28
CN109195963A (zh) 2019-01-11
IL261904B (en) 2020-09-30
CA3018346A1 (en) 2017-09-28
US10106528B2 (en) 2018-10-23
MX2018011194A (es) 2019-01-10
EP3433247A1 (en) 2019-01-30
US10590113B2 (en) 2020-03-17
BR112018068341A2 (pt) 2019-01-15
CO2018011105A2 (es) 2018-10-22
UY37169A (es) 2017-09-29
KR102433280B1 (ko) 2022-08-17
EP3433247B1 (en) 2021-09-08
AU2017238504B2 (en) 2021-05-27
ES2895124T3 (es) 2022-02-17
IL261904A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR110405A1 (es) Compuestos
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR109349A1 (es) Compuestos y usos
AR107912A1 (es) Inhibidores de ret
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR094300A1 (es) Derivados de quinolonas
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR113929A1 (es) Compuestos heterocíclicos
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR094702A1 (es) Compuestos de azabencimidazol
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos